Mechanistic biomarkers for clinical decision making in rheumatic diseases
- 19 February 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 9 (5), 267-276
- https://doi.org/10.1038/nrrheum.2013.14
Abstract
Biomarkers have the potential to improve all aspects of clinical practice, from diagnosis to monitoring of treatment effectiveness. In this Review, the authors use current and potential biomarkers from rheumatology and beyond to highlight the value of different types of biomarker in drug development and clinical decision making. Particular emphasis is placed on mechanistic biomarkers, which are rooted in disease pathogenesis and can provide an accurate reflection of disease activity. The use of biomarkers is becoming increasingly intrinsic to the practice of medicine and holds great promise for transforming the practice of rheumatology. Biomarkers have the potential to aid clinical diagnosis when symptoms are present or to provide a means of detecting early signs of disease when they are not. Some biomarkers can serve as early surrogates of eventual clinical outcomes or guide therapeutic decision making by enabling identification of individuals likely to respond to a specific therapy. Using biomarkers might reduce the costs of drug development by enabling individuals most likely to respond to be enrolled in clinical trials, thereby minimizing the number of participants required. In this Review, we discuss the current use and the potential of biomarkers in rheumatology and in select fields at the forefront of biomarker research. We emphasize the value of different types of biomarkers, addressing the concept of 'actionable' biomarkers, which can be used to guide clinical decision making, and 'mechanistic' biomarkers, a subtype of actionable biomarker that is embedded in disease pathogenesis and, therefore, represents a potentially superior biomarker. We provide examples of actionable and mechanistic biomarkers currently available, and discuss how development of such biomarkers could revolutionize clinical practice and drug development.Keywords
This publication has 104 references indexed in Scilit:
- Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary dataRheumatology International, 2011
- The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent mannerArthritis & Rheumatism, 2010
- Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll‐like receptor 4 and Fcγ receptorArthritis & Rheumatism, 2010
- MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell DevelopmentImmunity, 2010
- A four‐gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2010
- Molecular framework for response to imatinib mesylate in systemic sclerosisArthritis & Rheumatism, 2009
- What we can do and what we cannot do with fMRINature, 2008
- Expression of microRNA‐146 in rheumatoid arthritis synovial tissueArthritis & Rheumatism, 2008
- Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisArthritis & Rheumatism, 2007
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007